fasting vs glp 1 How should GLP-1 receptor agonists be managed in the perioperative period? The impact of intermittent fasting
Description
GLP-1 Receptor Agonist Market was valued at USD 27.27 Billion in 2025 and is expected to reach USD 138.15 Billion by 2035, growing at a CAGR of 17.61% from 20262035
Abstract Background Glucagonlike peptide1 receptor agonists (GLP1 RA) are increasingly being prescribed in drugnaive patients
Key pancreatic markers: Both amylase and lipase can rise modestly on GLP-1 medications without indicating pancreatitis this is a known pharmacological effect
Are the side effects of a particular GLP1 medication less severe than another
Effects of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
